Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    facet.materialart.
    Onkologe 15 (11), 1082-1090 
    Keywords: CANCER ; tumor ; Germany ; DIAGNOSIS ; DISEASE ; CENTERS ; ORGANIZATION ; ONCOLOGY ; Comprehensive cancer center ; Innovative clinical trials ; knowledge ; National Center for Tumor Diseases Heidelberg ; Standard operating procedure ; Translational cancer research
    Abstract: With the foundation of the National Center for Tumor Diseases (NCT) in 2004 Heidelberg has taken on a pioneering role. Supported by the German Cancer Aid (Deutsche Krebshilfe) Germany`s first Comprehensive Cancer Center was set up jointly by the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg University Hospital and the Heidelberg Thorax Clinic. The mission of this new type of organization is to combine optimum interdisciplinary patient care with excellence in translational cancer research. Parallel to the launch of the NCT in Heidelberg the German Cancer Aid has developed its concept for the support of "Oncology Excellence Centers" in order to create consistent structures and quality standards for improved care of cancer patients throughout Germany. The goal is to make sure that every cancer patient in Germany has access to a diagnosis and treatment according to the state of the art in medical knowledge. In addition to the NCT, 10 other Oncology Excellence Centers throughout Germany now receive funding. Mit der Gründung des Nationalen Centrums für Tumorerkrankungen (NCT) hat Heidelberg im Jahr 2004 eine Vorreiterrolle übernommen: Unterstützt von der Deutschen Krebshilfe richteten das Deutsche Krebsforschungszentrum (DKFZ), das Universitätsklinikum Heidelberg und die Thoraxklinik Heidelberg erstmalig in Deutschland ein Comprehensive Cancer Center ein. Diese neue Organisationsform tritt mit der Mission an, optimale interdisziplinäre Patientenversorgung mit Exzellenz in der translationalen Krebsforschung zu verbinden. Parallel zum Aufbau des NCT in Heidelberg entwickelte die Deutsche Krebshilfe ihr Konzept für den Förderschwerpunkt "Onkologische Spitzenzentren", um deutschlandweit einheitliche Strukturen und Qualitätsstandards für eine verbesserte Behandlung von Tumorpatienten zu schaffen. Das Ziel ist, jedem Krebspatienten in Deutschland den Zugang zu einer Diagnose und Behandlung auf dem aktuellen Stand des medizinischen Wissens anzubieten. Inzwischen werden neben dem NCT bundesweit 10 onkologische Spitzenzentren gefördert.
    Type of Publication: Journal article published
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; EXPRESSION ; GROWTH-FACTOR ; SURVIVAL ; tumor ; LONG-TERM ; GENE ; DELETION ; PROGRESSION ; AMPLIFICATION ; MUTATIONS ; expression profiling ; MALIGNANT BRAIN-TUMORS ; ONCOLOGY ; genetic pathways ; astrocytoma ; GLIOBLASTOMA-MULTIFORME ; GLIOBLASTOMA ; ARRAY-CGH ; FGFR2 ; INTEGRATED GENOMIC ANALYSIS ; IDH
    Abstract: To identify novel glioma-associated pathomechanisms and molecular markers, we performed an array-based comparative genomic hybridization analysis of 131 diffuse astrocytic gliomas, including 87 primary glioblastomas (pGBIV), 13 secondary glioblastomas (sGBIV), 19 anaplastic astrocytomas (AAIII) and 12 diffuse astrocytomas (AII). All tumors were additionally screened for IDH1 and IDH2 mutations. Expression profiling was performed for 74 tumors (42 pGBIV, 11 sGBIV, 13 AAIII, 8 AII). Unsupervised and supervised bioinformatic analyses revealed distinct genomic and expression profiles separating pGBIV from the other entities. Classifier expression signatures were strongly associated with the IDH1 gene mutation status. Within pGBIV, the rare subtype of IDH1 mutant tumors shared expression profiles with IDH1 mutant sGBIV and was associated with longer overall survival compared with IDH1 wild-type tumors. In patients with IDH1 wild-type pGBIV, PDGFRA gain or amplification as well as 19q gain were associated with patient outcome. Array-CGH analysis additionally revealed homozygous deletions of the FGFR2 gene at 10q26.13 in 2 pGBIV, with reduced FGFR2 mRNA levels being frequent in pGBIV and linked to poor outcome. In conclusion, we report that diffuse astrocytic gliomas can be separated into 2 major molecular groups with distinct genomic and mRNA profiles as well as IDH1 gene mutation status. In addition, our results suggest FGFR2 as a novel glioma-associated candidate tumor suppressor gene on the long arm of chromosome 10.
    Type of Publication: Journal article published
    PubMed ID: 20473936
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: RECEPTOR ; APOPTOSIS ; CANCER ; CANCER CELLS ; CELLS ; EXPRESSION ; tumor ; TUMOR-CELLS ; Germany ; human ; IN-VIVO ; THERAPY ; DEATH ; RISK ; PROTEIN ; DRUG ; LIGAND ; MECHANISM ; REDUCTION ; INDUCTION ; mechanisms ; DOWN-REGULATION ; treatment ; resistance ; UP-REGULATION ; sensitization ; TUMOR CELLS ; CANCER-THERAPY ; FLIP ; PPAR-GAMMA ; ACTIVATED RECEPTOR-GAMMA ; TRAIL-INDUCED APOPTOSIS ; neuroblastoma ; CASPASE ; RE ; INCREASE ; cancer therapy ; GLIOMA ; MALIGNANT GLIOMA ; brain tumors ; SURVIVIN ; LEVEL ; TUMOR-CELL ; downregulation ; AGONISTS ; APO2 LIGAND ; troglitazone
    Abstract: Induction of apoptosis by the death ligand TRAIL might be a promising therapeutic approach in cancer therapy. However, since not all tumor cells are sensitive to TRAIL, there is a need for the development of strategies to overcome TRAIL-resistance. The results of the present study show that the anti-diabetic drug troglitazone sensitizes human glioma and neuroblastoma cells to TRAIL-induced apoptosis. This process is accompanied by a substantial increase of active caspase 8 and active caspase 3, but it is independent of troglitazone's effects on the nuclear receptor PPAR-gamma. Troglitazone induces a pronounced reduction in protein expression levels of the anti-apoptotic FLICE-inhibitory protein (FLIP) without affecting FLIP mRNA levels. Further, protein and mRNA expression levels of the anti-apoptotic protein Survivin significantly decrease upon treatment with troglitazone. Moreover, sensitization to TRAIL is partly accompanied by an up-regulation of the TRAIL receptor, TRAIL-R2. A combined treatment with troglitazone and TRAIL might be a promising experimental therapy because troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via various mechanisms, thereby minimizing the risk of acquired tumor cell resistance
    Type of Publication: Journal article published
    PubMed ID: 16820965
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: RECEPTOR ; APOPTOSIS ; CANCER ; SURVIVAL ; tumor ; Germany ; THERAPY ; DIAGNOSIS ; DISEASE ; PATIENT ; treatment ; PARTICLES ; STAGE ; REGIONS ; CHRONIC LYMPHOCYTIC-LEUKEMIA ; TRANSLATION ; LEVEL ; cancer research ; CANCERS
    Abstract: Background: Despite great advances in basic oncology research, the situation in clinical oncology continues to be dissatisfying. Reasons for this include a lack of highly effective and specific types of treatment, late diagnosis of cancers (i.e., in advanced stages) and poor translation of new research results into clinical practice. Basic Situation: Knowledge in cancer research his grown exponentially over the past 2 decides. While our understanding of cancer development at the molecular level continues to improve, the actual transfer of these findings into practice is lagging behind today's possibilities. Examples from the German Cancer Research Center ("Deutsches Krebsforschungszentrum" [DKFZ]) and numerous other research institutes show that novel approaches in diagnostics and therapy do exist. Solution: To close the gap between basic research and clinical practice, completely new organizational forms in oncology are needed. Intelligent 0 models of integrated care of tumor patients shaped after US Comprehensive Cancer Centers may lead to fundamental improvements in clinical oncology, opening LIP a way to closely interlock research and clinical practice in order to create synergies for both sides. Such models are currently being established in different places in Germany, with the National Center for Tumor Diseases (NCT) Heidelberg occupying a special place due to its affiliation with the German Cancer Research Center. Moreover, collaboration with industry engaged in research needs to be intensified in order to advance new approaches in research to market readiness. Outlook: Cancer medicine of the future will be more specific, more individual and more interdisciplinary thin it is today. Cancer research, clinical oncology and industry engaged in research need to join forces in a strong alliance for the transfer of scientific findings into clinical application
    Type of Publication: Journal article published
    PubMed ID: 16501913
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...